The EC approval is based on a comprehensive submission package which demonstrated biosimilarity of Zirabev and the originator product.
This includes results from the phase 3 REFLECTIONS B739-03 clinical comparative study, which showed clinical equivalence and found no clinically meaningful differences between Zirabev and the originator product in patients with advanced non-squamous NSCLC.
As part of the overall REFLECTIONS clinical trial programme, Zirabev has been studied in approximately 400 subjects.
This approval follows the positive recommendation from the Committee for Medicinal Products for Human Use in December 2018.
Zirabev has also been filed for regulatory approval with the US Food and Drug Administration.
Pfizer has a portfolio of potential biosimilar candidates in mid- to late-stage development.
Zirabev is Pfizer's fifth biosimilar approved for use in Europe. Zirabev is a monoclonal antibody biosimilar of the originator biologic medicine, Avastin, which works by inhibiting the formation of new blood cells (angiogenesis) by specifically recognising and binding to vascular endothelial growth factor protein.
It has been studied in nearly 400 patients.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval